According to Archimedes Pharma, the European Commission has granted marketing authorization for the company’s PecFent fentanyl nasal spray for the treatment of breakthrough pain in adult cancer patients. Archimedes submitted an NDA for the product to the US FDA in 2009 and is waiting for US approval. Read the company’s press release.
